Journal of Geriatric Oncology xxx (2018) xxx–xxx

Contents lists available at ScienceDirect

Journal of Geriatric Oncology

Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study

Gerardo Rosati [a,*], Carmine Pinto [b,**], Francesca Di Fabio [c], Silvana Chiara [d], Ivan R. Lolli [e], Enzo M. Ruggeri [f], Libero Ciuffreda [g], Raimondo Ferrara [h], Lorenzo Antonuzzo [i], Daniela Adua [c], Patrizia Racca [g], Domenico Bilancia [a], Elena Benincasa [j], Maria Elena Stroppolo [j], Francesco Di Costanzo [i]

[a] *Medical Oncology, San Carlo Hospital, Potenza, Italy*
[b] *Medical Oncology, Santa Maria Nuova IRCCS Hospital, Reggio Emilia, Italy*
[c] *Medical Oncology, S. Orsola-Malpighi Policlinic Hospital, Bologna, Italy*
[d] *Medical Oncology, San Martino IRCCS University Hospital – National Cancer Institute, Genoa, Italy*
[e] *Medical Oncology, Saverio de Bellis IRCCS Hospital, Castellana Grotte, Italy*
[f] *Medical Oncology, Belcolle AUSL Hospital Viterbo, Viterbo, Italy*
[g] *Medical Oncology, Città della Salute e della Scienza, and San Giovanni Battista – Molinette Hospitals, Turin, Italy*
[h] *Medical Oncology, San Paolo Hospital, Milan, Italy*
[i] *Careggi University Hospital, Florence, Italy*
[j] *Merck Serono S.p.A., Rome, Italy*

ARTICLE INFO

Article history:
Received 27 July 2017
Received in revised form 8 January 2018
Accepted 23 January 2018
Available online xxxx

Keywords:
Cetuximab
Metastatic colon cancer
Elderly
Quality of life

ABSTRACT

Objectives: The influence of age (<70 years and ≥70 years) was retrospectively studied on the quality of life (QoL), incidence of side effects (including skin reactions) and efficacy of chemotherapy plus cetuximab in patients with *KRAS* wild type (WT) metastatic colorectal cancer (mCRC).
Methods: 225 patients of the Observed study (PS 0-1) were retrieved based on age (< 70 and ≥70 years) and evaluated through EORTC QLQ-C30 and DLQI questionnaires.
Results: The two patient groups (141 < 70 and 84 ≥ 70 years, respectively) were balanced with no differences in any of the clinical and pathological characteristics considered. Both groups underwent similar type of first-line chemotherapy plus cetuximab, treatment duration and compliance. Cetuximab therapy caused similar incidence of side effects and impact on QoL in older and younger patients. No difference was observed in progression free survival (PFS) and in disease control rates between the two patient populations. Median overall survival (OS) was higher in patients <70 (27 months, 95% CI: 22.7–31.27) than in patients ≥70 (19 months, 95% CI: 14.65–23.35) ($p = 0.002$), which is likely due to higher proportions of metastatic resection (27.0% vs 8.3%; $p = 0.001$) and utilization of second-line therapy in younger group (58.9% vs 42.9%; $p = 0.028$).
Conclusion: The current data suggest that fit older patients with mCRC can be safely treated with a cetuximab-based therapy, as QoL and safety profile do not seem to be affected by age. In addition, age did not impact the choice of chemotherapy to be associated to cetuximab and treatment compliance.

1. Introduction

In >40% of the cases, a colorectal cancer is diagnosed in patients older than 70 years [1]. In these patients often the choice of treatment is guided by data obtained in non-elderly or mixed population studies, which might compromise the quality of care in this age group [2,3]. Indeed, older patients with cancer are generally underrepresented in clinical trials; in fact, those >70 years old constitute <15% of most study cohorts [2], making the extrapolation of the results to this specific population difficult. Lower rates of chemotherapy and surgery in olderpatients with colon cancer across all stages of disease have been reported [4–7] and more frequently this subset of patients is more likely to be offered monotherapy than combination chemotherapy, even if the latter would probably be more efficacious [5].

Cetuximab is a monoclonal antibody specifically targeting the Epidermal Growth Factor Receptor (EGFR receptor) [8]. It has been

* Correspondence to: G. Rosati, Medical Oncology, San Carlo Hospital, Via Potito Petrone, 85100 Potenza, Italy.
** Correspondence to: C. Pinto, Medical Oncology, Santa Maria Nuova IRCCS Hospital, Viale Risorgimento, 57, 42123 Reggio Emilia, Italy.
E-mail addresses: oncogerry@yahoo.it (G. Rosati), Carmine.Pinto@asmn.re.it (C. Pinto).

https://doi.org/10.1016/j.jgo.2018.01.009

granted approval for the treatment of patients with RAS WT mCRC [9]. The clinical use of cetuximab is associated with a wide range of EGFR specific side-effects, mainly skin reactions, which could impact QoL as well as treatment compliance [1,10]. There are several reports that suggest that skin reaction is a surrogate of drug efficacy, as its severity has been shown to correlate with cetuximab clinical activity [11,12].

The very few data available on the use of anti-EGFR therapy, including cetuximab, in older patients with mCRC have been recently reviewed [13,14]. However, no data exist on the QoL of this patient population treated with cetuximab in the first-line setting. Recently, the results of considering the cetuximab-related skin reactions on patients's QoL in first-line routine setting have been reported by the ObservEr study, a observational, multicentre, prospective study aiming at investigating the QoL, safety and efficacy of first-line chemotherapy in combination with cetuximab in patients with *KRAS* WT mCRC [15]. The data suggested that cetuximab plus chemotherapy did not have a negative impact on QoL in mCRC patients in this real life clinical setting; in addition, a correlation between OS time and skin reactions severity was also observed, further corroborating the reported activity in clinical trials [11–13]. The score change on the EORTC QLQ-C30 QoL result was not associated with age in the multivariate analysis and the incidence of cetuximab related skin reactions showed no significant relationship to age [15].

The primary aim of this retrospective analysis was to study the influence of age (<70 years and ≥70 years) on the QoL through the incidence of skin reactions and other side effects as well as the efficacy of first-line chemotherapy in combination with cetuximab in patients with *KRAS* WT mCRC.

2. Experimental Methods

2.1. Patients and Treatment

The recently published ObservEr study [15] was an observational, multicentre, prospective study of QoL (primary endpoint), safety and efficacy of first-line chemotherapy in combination with cetuximab in patients with *KRAS* WT mCRC. Briefly, patients, prospectively enrolled in the study, with a measurable *KRAS* WT mCRC were eligible to receive cetuximab plus chemotherapy. In each center, all consecutive eligible patients were prospectively enrolled in the study with the exception of Performance Status 2 (PS2) or higher patients as per inclusion criteria (PS 0–1). Cetuximab was administered weekly with chemotherapy until disease progression or unacceptable toxicity, according to clinical practice at the center.

All patients who were eligible for participation provided written informed consent with all applicable governing regulations fulfilled before undergoing any study procedure. The study was performed in accordance with the Declaration of Helsinki.

2.2. Endpoints and Measurements

As cetuximab-related skin reactions generally develop within the first three weeks of therapy [16], QoL, the primary endpoint, was assessed within the first eight–twelve weeks of therapy to allow the assessment of the impact of skin reactions. Patient-reported outcomes were evaluated in all treated patients who had completed the baseline assessment and at least one post baseline assessment including the Dermatology Life Quality Index (DLQI) [17] and EORTC Quality of Life Questionnaire (QLQ) C30 version 3.0 (EORTC DataCenter, Brussels). Patients completed the DLQI questionnaire at baseline and weekly during the first 8 weeks, then at every evaluation visit scheduled per local clinical practice until disease progression. EORTC QLQ-C30 questionnaires were completed at baseline, at week eight–twelve (first post baseline evaluation), and every subsequent evaluation visit. DLQI total scores ranging from 0 to 1 were interpreted as no effect on dermatology-related QoL, from 2 to 5 as a small effect, 6 to 10 as a moderate effect, 11 to 20 as a very large effect, and 21 to 30 as an extremely large effect [17] In EORTC QLQ-C30 a ten-unit difference in the change in scores was considered clinically important or relevant [18,19].

Secondary endpoints evaluated were: incidence of cetuximab-related skin reaction and any serious adverse events (SAE), which were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version4.03; OS was defined as months from first cetuximab dose to death or last contact when a death had not been registered and the proportion of patients still alive at two years; PFS was calculated as the time from start of therapy to evidence of clinical/radiologic progression; and overall response rate (ORR) was defined as the percentage of complete responses (CR) and partial responses (PR) according to RECIST v1.1 (Revised RECIST guidelines version 1.1).

Treatment compliance (%) was calculated at total doses received/total planned doses ×100.

2.3. Statistical Methods

Descriptive summary statistics for continuous variables comprised number of non-missing observations, mean, standard deviation (SD), median, lower and upper quartiles, minimum, and maximum, where appropriate. Frequencies and percentages were provided for categorical variables. The Chi-square test was used to detect statistical differences between the frequencies in the two age groups. Changes in DLQI and EORTC-QLQ-C30 scores from baseline to first post-baseline visit were evaluated with mixed-design ANOVA. OS and PFS were analysed using the Kaplan–Meier method. *P*-values are reported and statistical significance declared for $p < 0.05$, without correction for multiplicity. All the analyses were carried out with the software Statistical Package for Social Science (SPSS) version 24.

3. Results

Between May 2011 and November 2012, 225 patients with *KRAS* WT mCRC entered the ObservEr study protocol to receive first-line treatment with cetuximab plus chemotherapy. The patients were stratified based on their age: <70 year ($n = 141$) (mean age 59.08 ± 0.58) and ≥70 ($n = 84$) (mean age 74.33 ± 0.30). Table 1 reports their main socio-demographics and baseline characteristics. The two groups were similar with no significant differences in all the variables considered.

No differences between the two age groups were observed in the type of administered first-line chemotherapy (irinotecan, oxaliplatin and other fluoropyrimidine-based) (Table 2) and in the percentage of patients treated with 5-fluorouracil/capecitabine plus cetuximab ($p = 0.095$). Table 2 also reports the main reasons for treatment discontinuation.

There was a trend of a longer duration of cetuximab treatment in patients <70 as compared to those ≥70 (157 days and 126 days, respectively). However, this difference did not reach a statistical significance ($p = 0.086$). Treatment compliance was similar in the two patient groups. In fact, a treatment compliance of >90% was observed in 91.5% and 94%, and was between 70 and 69% in 7.1% and 6% respectively in patients <70 and in those ≥70 ($p = 0.554$).

3.1. QoL

In both cases the changes in QoL were not different between the two age groups ($p = 0.132$ and $p = 0.405$, respectively), suggesting that cetuximab therapy had no detrimental effect on patient's QoL. Of note, a 16.7% deterioration of the Global Health status (GHS) was observed in the overall patient population enrolled in the ObservEr study. Similar GHS values were found when considering the two different patient age groups (Fig. 1A). When considering the different subscales of the EORTC-QLQ-C30 questionnaire, a decrease in mean values was observed, indicative of a slight worsening from baseline; however, again no significant differences between the two age groups were found (Fig. 1A). However, when the individual symptoms were considered,

Please cite this article as: Rosati G, et al, Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-lin..., J Geriatr Oncol (2018), https://doi.org/10.1016/j.jgo.2018.01.009